<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00031811</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069229</org_study_id>
    <secondary_id>OHSU-6312</secondary_id>
    <secondary_id>NCI-H02-0086</secondary_id>
    <nct_id>NCT00031811</nct_id>
  </id_info>
  <brief_title>Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer</brief_title>
  <official_title>Breast Cancer Survivors: Exercise and Raloxifene</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <brief_summary>
    <textblock>
      RATIONALE: Raloxifene and exercise may improve bone health and quality of life in breast&#xD;
      cancer survivors. Assessing bone health and quality of life may improve the ability to plan&#xD;
      treatment.&#xD;
&#xD;
      PURPOSE: Randomized clinical trial to study the effectiveness of raloxifene with or without&#xD;
      exercise compared with exercise alone in women who have been previously treated for breast&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the effects of raloxifene with or without exercise versus exercise alone on&#xD;
           bone reabsorption rate, bone formation rate, and bone density in women previously&#xD;
           treated for breast cancer.&#xD;
&#xD;
        -  Determine the effects of these regimens on the quality of life of these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, placebo-controlled, multicenter study. Patients are randomized&#xD;
      to one of four treatment arms.&#xD;
&#xD;
        -  Arm I: Patients are asked to exercise 5 days a week with instruction. Patients also&#xD;
           receive oral placebo once daily.&#xD;
&#xD;
        -  Arm II: Patients receive oral raloxifene once daily.&#xD;
&#xD;
        -  Arm III: Patients are asked to exercise as in arm I. Patients also receive oral&#xD;
           raloxifene once daily.&#xD;
&#xD;
        -  Arm IV: Patients receive oral placebo once daily. All patients receive oral calcium&#xD;
           supplements once daily. Treatment continues in all arms for 24 months in the absence of&#xD;
           disease progression or unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline and every 3 months during study.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 240 patients (60 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2001</start_date>
  <completion_date type="Actual">April 2003</completion_date>
  <primary_completion_date type="Actual">April 2003</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Supportive Care</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">80</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Menopausal Symptoms</condition>
  <condition>Osteoporosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raloxifene</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed breast cancer&#xD;
&#xD;
          -  No metastatic disease&#xD;
&#xD;
          -  At least 3 months but no more than 1 year since prior chemotherapy regimen including&#xD;
             doxorubicin or methotrexate and catabolic steroids (to prevent nausea, vomiting, fluid&#xD;
             retention, or hypersensitivity reactions)&#xD;
&#xD;
          -  No routine of regular strenuous exercise (more than 90 minutes per day 6 days/week OR&#xD;
             120 minutes per day 4 days/week)&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Estrogen and progesterone receptor negative OR&#xD;
&#xD;
               -  Estrogen and progesterone receptor positive&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Any age&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Postmenopausal (at diagnosis OR chemotherapy-induced)&#xD;
&#xD;
          -  No spontaneous menses for more than 6 months with increased follicle-stimulating&#xD;
             hormone and decreased estradiol&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Ambulatory&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No cardiac problems that would preclude exercise&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No respiratory problems that would preclude exercise&#xD;
&#xD;
          -  No chronic obstructive pulmonary disease&#xD;
&#xD;
          -  No oxygen dependence&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No endocrine disease (e.g., parathyroid hormone disorders) that would accelerate bone&#xD;
             turnover and loss&#xD;
&#xD;
          -  No musculoskeletal problems or other disease that would preclude exercise (e.g.,&#xD;
             movement-limiting arthritis, muscular dystrophy, or chronic fatigue syndrome)&#xD;
&#xD;
          -  No known cognitive or psychiatric disorders that would preclude study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior adjuvant or neoadjuvant chemotherapy allowed&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent tamoxifen&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Prior adjuvant radiotherapy after chemotherapy allowed&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent bisphosphonates&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Schwartz, FNP, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>March 8, 2002</study_first_submitted>
  <study_first_submitted_qc>August 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2003</study_first_posted>
  <last_update_submitted>May 24, 2012</last_update_submitted>
  <last_update_submitted_qc>May 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>osteoporosis</keyword>
  <keyword>menopausal symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raloxifene Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

